Evidence map›Paper›PMID 38496355›Full record

ArticleAmerican journal of clinical and experimental immunology2024

IFN-γ, IL-17, IL-22

Soolmaz Khansalar, Zahra Faghih, Shaghik Barani, Mehdi Kalani, Mohammad Reza Ataollahi, Zeinab Mohammadi, Sepideh Namdari, Kurosh Kalantar

Open access · bronzeAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of clinical and experimental immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Soolmaz KhansalarDepartment of Immunology, School of Medicine, Shiraz University of Medical Sciences Shiraz, Iran.
Zahra FaghihShiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences Shiraz, Iran.
Shaghik BaraniDepartment of Immunology, School of Medicine, Shiraz University of Medical Sciences Shiraz, Iran.
Mehdi KalaniDepartment of Immunology, Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences Shiraz, Iran.
Mohammad Reza AtaollahiDepartment of Immunology, School of Medicine, Fasa University of Medical Sciences Fasa, Iran.
Zeinab MohammadiDepartment of Radiation Oncology, Memorial Sloan-Kettering Cancer Center New York, NY, USA.
Sepideh NamdariDepartment of Immunology, School of Medicine, Shiraz University of Medical Sciences Shiraz, Iran.
Kurosh KalantarDepartment of Immunology, School of Medicine, Shiraz University of Medical Sciences Shiraz, Iran.
Shiraz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCD4

methodsTwenty-six HCV-infected patients and 26 healthy individuals were recruited. Peripheral blood mononuclear cells (PBMCs) were stained to separate CD4, IFN-γ, IL-17, and IL-22 producing cells using flow cytometry.

resultsResults showed that the mean expression of IL-22 in CD4

conclusionsOur findings indicate that Th22 cells may play a part in the immunopathology of HCV and show the associations between Thelper subsets and the clinical signs of the disease.

Indexed as

Hepatitis CinflammationTh1Th17Th22

Identifiers

PMID38496355
PMCPMC10944356
OpenAlexW4394764861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.